Home › Pfizer Receives U.S. FDA Accelerated Approval Of IBRANCE (palbociclib)
 

Keywords :   


Pfizer Receives U.S. FDA Accelerated Approval Of IBRANCE (palbociclib)

2015-02-04 06:14:13| drugdiscoveryonline Home Page

Pfizer Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease

Tags: approval receives accelerated fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »